Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.3% on Analyst Upgrade

Pulse Biosciences, Inc (NASDAQ:PLSE) shares were up 5.3% on Wednesday after Freedom Capmkts upgraded the stock to a strong-buy rating. The stock traded as high as $51.07 and last traded at $51.3950. Approximately 121,724 shares were traded during trading, a decline of 66% from the average daily volume of 362,152 shares. The stock had previously closed at $48.79.

PLSE has been the topic of a number of other research reports. Canaccord Genuity Group boosted their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price for the company. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Insider Buying and Selling at Pulse Biosciences

In related news, COO Liane Teplitsky purchased 1,036 shares of the stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $48.23 per share, with a total value of $49,966.28. Following the transaction, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at $49,966.28. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders purchased 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after acquiring an additional 65,884 shares during the last quarter. Deutsche Bank AG acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth about $687,000. Legal & General Group Plc acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth about $395,000. Panoramic Capital LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at about $2,719,000. Finally, BlackRock Inc. bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at about $40,672,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Stock Performance

The company has a market capitalization of $3.77 billion, a P/E ratio of -46.13 and a beta of 1.63. The stock’s fifty day moving average price is $39.87 and its 200-day moving average price is $28.84.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, research analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.